308 related articles for article (PubMed ID: 16006570)
1. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
3. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
[TBL] [Abstract][Full Text] [Related]
7. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P; Kreuzer KA; Pursche S; Bonin Mv; Leopold T; Baskaynak G; Dörken B; Ehninger G; Ottmann O; Jenke A; Bornhäuser M; Schleyer E
Cancer Chemother Pharmacol; 2004 Apr; 53(4):313-23. PubMed ID: 14658008
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
16. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
17. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Manley PW; Blasco F; Mestan J; Aichholz R
Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
[TBL] [Abstract][Full Text] [Related]
18. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
19. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R
Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
